Piezo Motion’s new partnership with iMotion will expand Piezo’s precision motor technologies and motion control offerings to the Rocky Mountain region
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, and iMotion Inc. together announce a distribution partnership. Piezo Motion is a developer and leading manufacturer of precision motor technology. iMotion Inc., based in Colorado, is a manufacturer’s representative serving leading original equipment manufacturers (“OEMs”) for over 15 years.
Piezo Motion’s unique technology will enable iMotion to provide their customers with unmatched accuracy in a compact motor. Piezo Motion’s multifaceted rotary and linear motors are built to provide a stable, accurate motor that is designed specifically for OEMs that require ultimate speed, size and accuracy.
“The value of the Piezo Motion’s unique technology fills a big gap in the market,” explains Darl Gagliano, president of iMotion. “With traditional piezo technology, the cost was always a factor. What is exciting is Piezo Motion brings this technology into a cost-competitive mode. We are very excited for this partnership.”
Piezo Motion motors are used globally for a variety of applications. These include laboratory instruments, biomedicine, optics, semiconductors, nanotechnology industries, and industrial electronic and automotive systems, along with an expanding portfolio of products that combine performance with dramatically lower cost over conventional piezo solutions.
“We are thrilled that Piezo Motion’s distribution network continues to grow and this partnership will provide local service to major OEMs,” said Hassan Kotob, chairman and CEO of Brain Scientific. “Piezo Motion’s technology continues to disrupt the market, and we are pleased to have iMotion’s expertise to further expand our reach.”
About Piezo Motion
Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today’s global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products.
About Brain Scientific
Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap and NeuroEEG are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products or investor relations, please visit brainscientific.com.
About iMotion
iMotion (imotioninc.com) is based in Castle Rock, Colorado, and is a manufacturer’s representative serving the OEM motion control industry in the Rocky Mountain region. With more than 80 years of experience in this area, iMotion Inc. has been able to assemble the premier manufacturers of motion control products and have the knowledge and experience to help apply those products in a manner that will maximize opportunity for success in the design effort. iMotion is an expert at providing solutions, from simple to unique applications. The company remains focused on the OEM motion control market while expanding into biotech and developing technology industries.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company’s future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company’s inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company’s inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company’s raw materials; and the failure to implement the company’s business plans or strategies, including as a result of the closing of the merger with Piezo Motion. Some of these and other factors are identified and described in more detail in the company’s filings with the SEC. The company does not undertake to update these forward-looking statements.
CONTACTS
INVESTORS
ir@brainscientific.com
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
New leadership roles highlight Hallmark’s unique vendor-neutral approach to helping health systems build flexible, efficient,…
Company Celebrates Continued Worldwide Progress Toward Data-Driven Surgery SAN FRANCISCO and BERLIN, Dec. 23, 2024…
SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Medit has launched a mobile app, MEDIT…